Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Primary Purpose: Treatment
James M. Oleske, MD
University of Medicine and Dentistry New Jersey
United States: Federal Government
|New Jersey Medical School||Newark, New Jersey 07103-2714|